JP2007528889A - 吸入製剤 - Google Patents

吸入製剤 Download PDF

Info

Publication number
JP2007528889A
JP2007528889A JP2007502412A JP2007502412A JP2007528889A JP 2007528889 A JP2007528889 A JP 2007528889A JP 2007502412 A JP2007502412 A JP 2007502412A JP 2007502412 A JP2007502412 A JP 2007502412A JP 2007528889 A JP2007528889 A JP 2007528889A
Authority
JP
Japan
Prior art keywords
salmeterol
inhalation
formulation
acceptable salt
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007502412A
Other languages
English (en)
Japanese (ja)
Inventor
ルルラ アマル
マルホトラ ゲエナ
Original Assignee
シプラ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シプラ・リミテッド filed Critical シプラ・リミテッド
Publication of JP2007528889A publication Critical patent/JP2007528889A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007502412A 2004-03-12 2005-03-14 吸入製剤 Pending JP2007528889A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN312MU2004 2004-03-12
PCT/GB2005/001119 WO2005087192A2 (en) 2004-03-12 2005-03-14 Salmeterol inhalation formulations

Publications (1)

Publication Number Publication Date
JP2007528889A true JP2007528889A (ja) 2007-10-18

Family

ID=34962995

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007502412A Pending JP2007528889A (ja) 2004-03-12 2005-03-14 吸入製剤

Country Status (9)

Country Link
EP (1) EP1732526A2 (ru)
JP (1) JP2007528889A (ru)
KR (1) KR20060135873A (ru)
AP (1) AP2006003734A0 (ru)
IL (1) IL177596A0 (ru)
MA (1) MA28462B1 (ru)
RU (1) RU2006136025A (ru)
WO (1) WO2005087192A2 (ru)
ZA (1) ZA200606801B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016052897A1 (en) * 2014-09-30 2016-04-07 Hanmi Pharm. Co., Ltd. Dry powder for inhalation formulation having improved stability of combined active ingredients

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03167120A (ja) * 1989-09-08 1991-07-19 Glaxo Group Ltd 呼吸疾患治療薬
JP2002512952A (ja) * 1998-04-24 2002-05-08 グラクソ グループ リミテッド サルメテロールキナホエートのエアロゾル製剤
WO2004019985A1 (en) * 2002-08-29 2004-03-11 Cipla Ltd Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB2235627B (en) * 1989-09-08 1993-09-01 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
ATE250439T1 (de) * 1995-04-14 2003-10-15 Smithkline Beecham Corp Dosierinhalator für salmeterol
US6919325B2 (en) * 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03167120A (ja) * 1989-09-08 1991-07-19 Glaxo Group Ltd 呼吸疾患治療薬
JP2002512952A (ja) * 1998-04-24 2002-05-08 グラクソ グループ リミテッド サルメテロールキナホエートのエアロゾル製剤
WO2004019985A1 (en) * 2002-08-29 2004-03-11 Cipla Ltd Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids

Also Published As

Publication number Publication date
ZA200606801B (en) 2008-05-28
WO2005087192A3 (en) 2006-06-15
IL177596A0 (en) 2006-12-10
EP1732526A2 (en) 2006-12-20
KR20060135873A (ko) 2006-12-29
MA28462B1 (fr) 2007-03-01
RU2006136025A (ru) 2008-04-20
WO2005087192A2 (en) 2005-09-22
AP2006003734A0 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
RU2327450C2 (ru) Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды
EP2010190B1 (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
JP3342484B2 (ja) 新規な配合
JP2008512434A (ja) ベータ擬似剤の異性体及び抗コリン作用剤を含む医薬組成物
US20150150787A1 (en) Compositions, methods & systems for respiratory delivery of three or more active agents
MX2007007378A (es) Compuestos y composiciones farmaceuticas.
KR101475262B1 (ko) 천식 치료에 사용되는 흡입용 복합 조성물
US20130295023A1 (en) Inhalation Solutions
JP2004507494A (ja) サルメテロールとプロピオン酸フルチカゾンとの合剤の使用
WO2013026269A1 (zh) 制备用于治疗呼吸道疾病的定量喷雾吸入剂的工艺方法
Vastagh et al. Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC
JP2007528889A (ja) 吸入製剤
RU2678992C2 (ru) Фармацевтическая композиция, содержащая арформотерол и флутиказона фуроат
RU2457832C2 (ru) Состав на основе тровентола
MXPA00009981A (en) Use of a glucocorticosteroid for the manufacture of a medicament for treating mild/early forms of copd (chronic obstructive pulmonary disease)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111108